Healthcare Worker Study Cohort to Determine the Level and Durability of Cellular and Humoral Immune Responses after Two Doses of SARS-CoV-2 Vaccination.
SARS-CoV-2
cellular and humoral immune responses
second dose
variants
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
24 Oct 2022
24 Oct 2022
Historique:
received:
30
05
2022
revised:
28
06
2022
accepted:
29
06
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
We prospectively studied immunological response against SARS-CoV-2 after vaccination among healthcare workers without (group A) and with previous infection (group B). The analyses were collected at T0 (before the BNT162b2), T1 (before the second dose), T2 and T6 (1 and 6 months after the second dose). For cellular immune response, the activation-induced cell marker assay was performed with CD4 and CD8 Spike peptide megapools expressed as Stimulation Index. For humoral immune response, we determined antibodies to Spike-1 and nucleocapsid protein. The linear mixed model compared specific times to T0. The CD4+ Spike response overall rate of change was significant at T1 (p = 0.038) and at T2 (p < 0.001), while decreasing at T6. For CD8+ Spike reactivity, the interaction between the time and group was significant (p = 0.0265), and the p value for group comparison was significant at the baseline (p = 0.0030) with higher SI in previously infected subjects. Overall, the anti-S Abs significantly increased from T1 to T6 compared to T0. The group B at T6 retained high anti-S titer (p < 0.001). At T6, in both groups we found a persistent humoral response and a high CD4+ T cell response able to cross recognize SARS-COV-2 variants including epsilon, even if not a circulating virus at that time.
Identifiants
pubmed: 36366293
pii: vaccines10111784
doi: 10.3390/vaccines10111784
pmc: PMC9697204
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 to A.S.
ID : 75N93021C00
Références
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Nat Commun. 2021 Aug 17;12(1):5061
pubmed: 34404775
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Euro Surveill. 2021 Oct;26(41):
pubmed: 34651577
J Immunol Res. 2015;2015:763461
pubmed: 26568965
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Nature. 2017 Dec 21;552(7685):362-367
pubmed: 29236685
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Med (N Y). 2021 Mar 12;2(3):281-295.e4
pubmed: 33589885
Nature. 2022 Jan;601(7891):110-117
pubmed: 34758478
Inflammopharmacology. 2021 Aug;29(4):1075-1090
pubmed: 34241782
Open Forum Infect Dis. 2022 Apr 18;9(6):ofac138
pubmed: 35611346
Lancet. 2022 Mar 5;399(10328):924-944
pubmed: 35202601
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Med (N Y). 2021 Jun 11;2(6):682-688.e4
pubmed: 33851143
J Med Virol. 2022 May;94(5):1825-1832
pubmed: 35023191
Euro Surveill. 2021 Jul;26(28):
pubmed: 34269175
Nature. 2021 Sep;597(7875):268-273
pubmed: 34320609
Science. 2021 Apr 30;:
pubmed: 33931567
J Immunol. 2016 Aug 1;197(3):983-93
pubmed: 27342848
Immunity. 2020 Dec 15;53(6):1281-1295.e5
pubmed: 33296685
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
N Engl J Med. 2022 Mar 31;386(13):1207-1220
pubmed: 35172051
JCI Insight. 2021 Dec 22;6(24):
pubmed: 34935643
PLoS One. 2017 Oct 24;12(10):e0186998
pubmed: 29065175
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
Lancet. 2020 May 23;395(10237):1608-1610
pubmed: 32401714
Wellcome Open Res. 2020 Jul 28;5:179
pubmed: 33537459
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
iScience. 2022 Feb 18;25(2):103743
pubmed: 35018336
J Clin Virol. 2020 Aug;129:104480
pubmed: 32505777
J Immunol. 2007 Apr 1;178(7):4112-9
pubmed: 17371966
Vaccines (Basel). 2022 Feb 06;10(2):
pubmed: 35214705
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):1063-1071
pubmed: 33534090
Nature. 2021 Jul;595(7868):572-577
pubmed: 34044428
Nat Immunol. 2001 May;2(5):415-22
pubmed: 11323695